Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients

This study has been terminated.
(Business decision not to continue development)
Information provided by (Responsible Party):
Hospira, Inc. Identifier:
First received: June 26, 2007
Last updated: January 10, 2012
Last verified: January 2012
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: August 2011
  Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)